Market Highlights:
Nifedipine belongs to a calcium channel blocker that comes under the dihydropyridine subclass. Primary uses of nifedipine are anti-hypertensive and anti-anginal medications. It relaxes the muscles of heart and blood vessels Nifedipine is used to treat hypertension (high blood pressure) and angina (chest pain). Nifedipine tablets come in an extended-release form and sustained released form of the drug. Nifedipine is also available in immediate-release oral capsules. They are also available in a generic drug. Nifedipine is used to lower blood pressure in people with hypertension, also used as part of combination therapy. The market study is being classified by Type (Initial dose(30 to 60 mg orally once a day), Maintenance dose (30 to 90 mg orally once a day) and Maximum dose (Up to 120 mg/day)), by Application (Heart Failure, Raynauds Syndrome, Cephalalgia, Bronchial Asthma, Hypertension, Angina Pectoris Prophylaxis, Angina Pectoris and Primary Pulmonary Hypertension) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Key Players:
The prominent players in the Nifedipine are Pfizer (United States), Bayer (Germany), Actavis (United States), Teva (Israel), Shyndec (China), Honglin Pharma (China), Qingdao Huanghai Pharmaceutical (China), Yabao (China), Global Pharm (United States) and Huazhong Pharmaceutical Co Ltd (China).

Major Market Development Highlights
In August 2019 Bayer acquires BlueRock Therapeutics to build a leading position in cell therapy. Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology, and immunology.
In January 2020 granted approval for Bayer application for nifurtimox to treat pediatric patients with Chagas.A new formulation for the weight-adjusted treatment of pediatric Chagas patients age 0-18 targets most vulnerable patient group / Submission based on results of CHICO phase III clinical study of nifurtimox in pediatric patients with Chagas disease as well as pre-clinical data / Fight against Neglected Tropical Diseases part of Bayer’s Sustainability Strategy.

Key Questions Answered in the Report
What will the Nifedipine Market size and the growth rate be in Future?
What are the key factors driving the Nifedipine Market?
What are the key market trends and macro-economic impacting the growth of the Nifedipine Market?
What are the challenges to market growth?
Who are the key vendors in the Nifedipine Market?
What are the market opportunities and threats faced by the vendors in the Nifedipine Market?
Trending factors influencing the market shares of the Vendors.
What are the key outcomes of the five forces analysis of the Nifedipine Market?

Have a look at complete Table of Content: https://www.advancemarketanalytics.com/reports/29175-global-nifedipine-market.

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Nifedipine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Nifedipine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers, Hospital and diagnostic centers, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Industry Associate and Downstream Vendors.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.